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INTRODUCTION
Malaria is a disease caused by infection with proto-
zoan parasite genus Plasmodium, of which four spe-
cies infect humans. It produces up to 500 million new
infections and 2 million deaths every year (1). Chemo-
therapy and vector control have been insufficient
to control the disease because of the emergence and
spread of parasites and their vectors resistant to these o
ld chemical based control methods (2, 3). Thus, ma-
laria vaccines are urgently needed to control malaria
especially caused by two major species, P. falciparum
and P. vivax. The malaria parasite has a complicat-
ed life cycle (Fig. 1), which makes difficult to devel-
op a universal, effective and long lasting vaccine.
However, several studies suggested that vaccines
against each parasite stage are feasible as part of a
control strategy.
LIFE CYCLE OF MALARIA PARASITE AND
VACCINE TARGETS
Infection is initiated by inoculation of sporozoites,
an infectious form of the parasite, through mosqui-
to bites. Once inoculated, sporozoites spend less than
30 minutes in the blood before entering heptocytes
or being eradicated. In heptocytes, a single sporozoite
develops into 30,000-40,000 merozoites, each of which,
when released into the bloodstream, continues its
life cycle in red blood cells. Specific antibodies to
sporozoites can inhibit entry to hepatocytes (4). During
hepatic development, a variety of liver-stage-specific
antigens are synthesized by the parasite and are
presented in context with MHC class I molecules
and recognized by CD8+ T cells (5). Vaccines against
parasites before merozoite release called liver-stage
vaccine are expected to induce antibodies that in-
hibit invasion of hepatocytes and cytotoxic T cells
that destroy infected liver cells. Successful vaccines
can reduce the chance of a person becoming sick
because all symptoms appear during the asexual
growth stage in the blood cycle.
In the bloodstream each merozoite invades a red
blood cell and asexually divides up to 24 merozites
in the host cell over a period of 2 to 3 days. Mature
parasites rupture the host cell to infect new red
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blood cells, which causes the periodic elevation of
body temperature (fever). Antibodies to merozoite
can inhibit invasion of red blood cells (6). Antibod-
ies to parasite-derived molecules on the surface of
infected red blood cells can prevent adhesion to cap-
illary endothelial cells, responsible for pathogenicity
of major complications such as cerebral malaria. Vac-
cines against parasites undergoing the blood cycle
are called blood-stage vaccines. Effective vaccines
will reduce disease severity and the risk of death
during infection.
A part of the blood-stage parasite develops to a
sexual parasite, male and female gametocytes, in-
stead of repeating the asexual cycle. Gametocytes
are ingested by mosquitoes during blood sucking
and they undergo the sexual process (sporogony).
The TBVs focused on here are designed to prevent
parasites spread by inhibiting development of para-
sites within mosquito vectors.
TRANSMISSION-BLOCKING VACCINE AND ITS EFFECT
Gametocytes ingested by susceptible species of
mosquito shed the host erythrocyte and the female
develops into a macrogamete and the male becomes
eight microgametes. Gametes mate, and the ferti-
lized zygotes transform to motile ookinetes that pen-
etrate the mosquito midgut peritrophic matrix and
midgut epithelial cells. Then they develop into oocysts
on the serous membrane. Matured oocysts release
sporozoites that migrate to the salivary glands to
prepare the next infection. TBVs are designed to
induce antibodies that disrupt at least one of these
steps when ingested with parasite-infected blood.
Unlike two other malaria vaccines, TBV does not
provide direct protection to individuals infected vac-
cine. However, this vaccine was suggested to be
one of the important strategies for integrated ma-
laria control program. Primarily, TBV will reduce
the incidence of malaria patients in the community
whose residence is vaccinated. In addition, this
would control the escape of parasite mutants from
vaccines targeted to other stages of the parasites life
cycle (7), which would prolong the effective life of
other malaria vaccines.
TRANSMISSION-BLOCKING VACCINE CANDIDATES
Target molecules for TBV must be expressed by
the sexual stage parasites, gametocytes to ookinetes
(Fig. 2). Several candidate molecules expressed by
the sexual stage parasites have been reported. They
are mostly from P. falciparum responsible for nine
of ten deaths.
Fig. 1. Life cycle of malaria parasite and vaccines against different stage parasites (from Ref. 6). Liver-stage vaccines target sporozoites
and parasite in hepatocytes. Blood-stage vaccines prevent repeating blood cycles. Transmission-blocking vaccines are de-
signed to interfere with parasite development in mosquito vectors.
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1. Pfs230
Pfs230 is cloned as a molecule expressed by
gametocytes of P. falciprum and its molecular size
is 230 kDa (8). The expression remains after gametes
fertilize and transform to zygotes (9). Antibodies
against Pfs230 completely block transmission of the
parasite to mosquito vectors when ingested with a
gametocytemic bloodmeal through a membrane-feeding
apparatus (10).
2. Pfs48/45
Pfs48/45 is also a molecule expressed by gametocytes
of P. falciparum and shows on electric doublet of
48 and 45 kDa on polyacrylamide gel electropho-
resis (11). The expression pattern is similar to that
of Pfs230. A rodent parasite disrupted gene encoding
P48/45 homologue demonstrates that P48/45 fami-
ly is essential for male gamete fertility (12). Anti-
bodies against this molecule also completely block
parasite transmission to mosquitoes (13).
3. Pfg27
Pfg27 is expressed as early as gametocytogenesis
(14). P. falciparum disrupted gene encoding Pfg27
fails to develop the sexual stage parasites, suggest-
ing that this molecule functions at an early stage
of gametocytogenesis in vertebrate hosts (15). This
also generates antibodies that block parasite trans-
mission (16).
4. Chitinase
Ookinetes secrete chitinase, an enzyme that
hydrolyses chitin, a polymerized form of N-acetyl
glucosamine (17). Chitin is a major component of
mosquito peritrophic matrix and its rigid structure
was suggested to function as a physical barrier to
parasite invasion. Chitinase is essential to penetrate
the peritrophic matrix because a chitinase inhibi-
tor and disruptant of chitinase gene suppresses
oocyst formation (18, 19). Thus, this represents a
target molecule not only for the transmission-blocking
vaccine strategy but also drug development (20).
5. Pfs25/Pvs25, Pfs28/Pvs28
The leading candidates for a transmission-blocking
vaccine against P. falciparum have been cloned (21).
Pfs25 and Pfs28 are expressed on the surface of
ookinetes and are composed of four tandem epidermal
growth factor-like domains, putatively anchored to the sur-
face membrane by a glycosylphosphatidylinositol-attached
motif. Yeast-produced recombinant proteins elicit
transmission-blocking antibodies in animal models
Fig. 2. Parasite development in mosquito vectors and transmission-blocking vaccine candidates. Gametocytes in human hosts in-
gested by mosquito vectors become gametes then fertilize to transform zygotes that develop motile ookinetes. TBV induces
antibodies against molecules expressed by gametocytes to ookinetes. Six candidates are listed and their expression pattern
is indicated with black lines.
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(22). Their homologs of P. vivax, Pvs25 and Pvs28,
were recently cloned (23).
DEVELOPMENT OF TBV AGAINST VIVAX
MALARIA BASED ON Pvs25
Among these vaccine candidates, the most advanced
is P25 and P28 family proteins of P. falciparum and
P. vivax , Pfs25, 28 and Pvs25, 28. TBV against P. vivax
based on Pvs25 and Pvs28 were recently developed.
Pvs25 and Pvs28 are successfully expressed as recom-
binant proteins by yeast Saccharomyces cerevisiae
and the products are highly immunogenic and in-
duce antibodies that block oocyst formation in mos-
quito when mixed with a gametocytemic blood meal
(24). Thus, both proteins are potentially vaccine can-
didates. Gene knock-out experiments demonstrate
that rodent malaria parasites deficient for the P25
and P28 proteins fail to generate oocysts in mosqui-
toes, suggesting a synergistic role in oocyst forma-
tion (25). This suggests that maximum inhibition
will be obtained when antibodies to Pvs25 and Pvs28
exist. However, detailed experiments revealed that
no synergistic effect of anti-Pvs25 and -Pvs28 anti-
serum on oocyst formation was observed (26). To-
gether with low yield, the high frequency of vari-
ants, and the unresponsiveness in mice in MHC-dependent
manner of Pvs28, a single use of Pvs25 as a vac-
cine was determined as the best candidate for TBV
against P. vivax. Thereafter, Pvs25 has been tested
for immunogenicity in non-human primates (27). A
clinical grade Pvs25 is currently being produced
and phase I trials will soon be conducted at the
Malaria Vaccine Development Unit, NIH (Stowers,
personal communication).
OBSTACLES TO BE OVERCOME
The most serious obstacles to developing a ma-
laria vaccine (and other vaccines) are antigenic di-
versity, lack of in vitro assay system, difficulty in
conducting human trials, and selection of an adjuvant
delivery system. Comparing with two other malaria
vaccines, these obstacles are easier to be overcome
for the TBV based on Pvs25. Antigenic variation is
much less frequent in P25 family proteins (23, 28).
The molecules are not exposed to host immune
systems because they are expressed only after fer-
tilization in the mosquito. However, this results in
another problem. Immune responses to the vaccine
would not be boosted during natural infection. There-
fore, formulations may need to be developed to ex-
tend the effective life of TBV-induced immunity.
The immune mechanism of TBV is antibody-mediated
inhibition of parasites’ development in mosquitoes.
This has enabled an ex vivo assay to be established.
Mosquitoes were fed with gametocyte-infected blood
through a membrane in the presence of immune
serum. Thereafter, the number of oocysts is counted.
Using this assay, the transmission-blocking activ-
ity of serum from human volunteers will be evalu-
ated without requiring experimental infection of each
volunteer with malaria. This is a big advantage to
design clinical trials. In terms of the adjuvant and
delivery systems, we could be optimistic, because
alum adjuvant (only adjuvant applicable for human
use) combined with Pvs25 could induce high titers
of antibody that has strong a transmission-blocking
activity in rodents and non-human primates. More-
over, DNA vaccination also induces a high titer of
antibodies (29, Kumar, personal communication).
CONCLUDING REMARKS
Although TBV does not provide direct protection
to individuals, this is an important strategy for con-
trolling malaria. Since TBV could prevent the spread
of escape of mutants from other vaccines, this must
be a member of a multi-component malaria vaccine.
The biggest problem common to developing malaria
vaccine is the relatively low level of commercial in-
terest. This is because the potential market with
endemic malaria is mainly in the developing coun-
tries who do not have economic support. However,
economic support will be obtained in the future (ex.
The Bill Gates Foundation for Malaria Vaccine De-
velopment was established).
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